Form 4: Arcutis CEO Todd Watanabe Executes Tax-Related Stock Sale

Arcutis Biotherapeutics CEO Todd Watanabe sold 3,172 shares of common stock to satisfy tax withholding obligations related to RSU vesting.

Summary

• Todd Watanabe, President and CEO of Arcutis Biotherapeutics, sold 3,172 shares of common stock on May 4, 2026.
• The sale was executed at a weighted average price of $23.6106 per share, with individual transaction prices ranging from $23.16 to $23.93.
• The transaction was conducted pursuant to a Rule 10b5-1 trading plan.
• The sale was specifically intended to cover tax withholding obligations resulting from the vesting of Restricted Stock Units (RSUs).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transaction is purely administrative and related to tax obligations rather than a discretionary divestment.

Positives

• The transaction was routine and non-discretionary, specifically executed to satisfy tax obligations rather than reflecting a change in market sentiment by the CEO.

Negatives

• The sale reduces the direct beneficial ownership of the CEO by 3,172 shares.

Risks

• Reliance on Rule 10b5-1 plans for liquidity can lead to periodic selling pressure on the stock.

Future Outlook

No forward-looking guidance regarding company operations was provided in this filing.

Management Comments

• The Reporting Person undertakes to provide full information regarding the number of shares sold at each respective price within the range upon request.

Industry Context

StockSavvy.ai notes that routine tax-related selling by executives is a standard practice in the biotechnology sector and generally does not signal a lack of confidence in the company's long-term strategic direction.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is a standard corporate governance practice for executives to avoid potential insider trading concerns.
• The sale of shares to cover tax withholding upon RSU vesting is a common administrative event for public company officers.

Related Party Transactions

• The filing discloses holdings in various trusts and an LLC (Watanabe Ventures, LLC) where the reporting person serves as trustee or officer, though these are standard disclosures for executive beneficial ownership.

Stakeholder Impact

• Minimal impact on shareholders as the sale was pre-planned and tax-related.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

ARQT, Arcutis Biotherapeutics, Insider Trading, Form 4, Biotech, Executive Compensation